adminの記事一覧

Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.

Clin Nephrol. 70(5): 385-392, 2008.PubMed

L-Type Fatty Acid Binding Protein Transgenic Mouse as a Novel Tool to Explore Cytotoxicity to Renal Proximal Tubules.

Drug Metab. Pharmacokinet. 23(4): 271-278, 2008.PubMed

Renal L-type fatty acid-binding protein in acute ischemic injury.

J Am Soc Nephrol. 18(11): 2894-2902, 2007.PubMed

Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.

Diabetologia. 50(2): 490-492, 2007.PubMed

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.

Am J Med Sci. 333(6): 321-326, 2007.PubMed

Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.

Am J Hypertens. 20(11): 1195-1201, 2007.PubMed

A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure.

Kidney Int. 72(3): 348-358, 2007.PubMed

Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.

Am J Kidney Dis. 47(3): 439-444, 2006.PubMed

Cigarette smoking affects urinary liver-type fatty acid-binding protein concentration in patients with early diabetic nephropathy.

Diabetes Care. 29(7): 1717, 2006.PubMed

Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.

Clin Nephrol. 65(1): 1-6, 2006.PubMed